- Investing Ideas
- Swedish Pharmaceuticals & Biotech Potentially Undervalued Small Caps
Swedish Pharmaceuticals & Biotech Potentially Undervalued Small Caps
Results
6
Value score of at least 4 focused on companies with a low market cap.
6 companies
Cantargia
Market Cap: SEK 464.7m
A biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases.
CANTA
SEK 1.87
7D
2.7%
1Y
-41.5%
Sprint Bioscience
Market Cap: SEK 392.5m
A pharmaceutical company, engages in the development of drug candidates to treat cancer in Sweden.
SPRINT
SEK 3.72
7D
3.6%
1Y
534.8%
Ascelia Pharma
Market Cap: SEK 69.2m
A biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden.
ACE
SEK 0.52
7D
1.6%
1Y
-88.9%
Double Bond Pharmaceutical International
Market Cap: SEK 12.9m
A pharmaceutical company, engages in the development and commercialization of approaches for the treatment of oncological and infectious diseases.
DBP B
SEK 0.12
7D
9.1%
1Y
-72.7%
ODI Pharma
Market Cap: SEK 41.8m
A pharmaceutical company, engages in the production and distribution of pharmaceutical cannabis and cosmetics products in Europe.
ODI
SEK 2.28
7D
-10.2%
1Y
38.2%
Subgen AI
Market Cap: SEK 56.6m
Develops artificial intelligence-based models and applications to control data for government and businesses.
SUBGEN
SEK 0.056
7D
-13.1%
1Y
n/a